Literature DB >> 3301679

Activation and binding of C3 by Candida albicans.

T R Kozel, R R Brown, G S Pfrommer.   

Abstract

Interaction with components of the complement system is an important aspect of the pathogenesis of infection by Candida albicans. The key role of C3 as an opsonic ligand and as an element in amplification of complement activation led us to examine several factors that influence the activation and binding of C3 cleavage fragments to the yeast. Activation and binding of C3 were determined by use of normal human serum containing 125I-labeled C3. Incubation of yeast-phase cells in 20% serum led to deposition of 2.5 X 10(5) to 3.0 X 10(5) molecules of C3 per yeast cell. Binding of C3 was absent in serum that was heat inactivated for 30 min at 37 degrees C or in serum that was chelated with EDTA. Chelation of serum with EGTA [ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid] reduced binding of C3 fragments by 31%. These results suggest that the alternative complement pathway is the primary mechanism for activation and binding of C3 fragments to C. albicans. Bound C3 could be partially removed (50%) by treatment with 1.0 M hydroxylamine. In contrast, 1.0 M hydroxylamine removed 98% of the C3 fragments bound to encapsulated Cryptococcus neoformans. These results suggest that ester bonds are the primary mechanism for binding C3 to C. neoformans, whereas binding of C3 to C. albicans involves both ester and amide bonds. Monoclonal antibodies specific for C3c and an iC3b neoantigen were used to identify the fragment of C3 that was bound to C. albicans. The results showed that the primary fragment bound to the yeast was C3b. An examination of the kinetics of activation and binding of C3 fragments showed that activation and binding were very rapid. Near-maximal binding occurred after a 2.5- to 5-min incubation period. In contrast, activation and binding of C3 fragments to C. neoformans proceeded at a slower rate, with maximal binding requiring 10 to 20 min. These results indicate that activation and binding of C3 fragments by the yeasts C. albicans and C. neoformans differ in several important characteristics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3301679      PMCID: PMC260620          DOI: 10.1128/iai.55.8.1890-1894.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

2.  Interaction between the third complement protein and cell surface macromolecules.

Authors:  S K Law; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

3.  Alternative pathway of complement activation by Candida albicans.

Authors:  Y H Thong; A Ferrante
Journal:  Aust N Z J Med       Date:  1978-12

4.  Activation of the alternate pathway of human complements by rabbit cells.

Authors:  T A Platts-Mills; K Ishizaka
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

5.  The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.

Authors:  K J Gadd; K B Reid
Journal:  Biochem J       Date:  1981-05-01       Impact factor: 3.857

6.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

7.  An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida Albicans.

Authors:  K L Lee; H R Buckley; C C Campbell
Journal:  Sabouraudia       Date:  1975-07

8.  Role of complement in host defense against experimental disseminated candidiasis.

Authors:  J A Gelfand; D L Hurley; A S Fauci; M M Frank
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

9.  Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.

Authors:  T R Kozel; G S Pfrommer
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

10.  Assessment of phagocytic and antimicrobial activity of human granulocytes.

Authors:  L Schmid; K Brune
Journal:  Infect Immun       Date:  1974-11       Impact factor: 3.441

View more
  19 in total

1.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Effect of glutaraldehyde fixation on cell surface binding capacity of Candida albicans.

Authors:  J Mleczko; L L Litke; H S Larsen; W L Chaffin
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

3.  Integrin-based diffusion barrier separates membrane domains enabling the formation of microbiostatic frustrated phagosomes.

Authors:  Michelle E Maxson; Xenia Naj; Teresa R O'Meara; Jonathan D Plumb; Leah E Cowen; Sergio Grinstein
Journal:  Elife       Date:  2018-03-19       Impact factor: 8.140

4.  Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells.

Authors:  S L Newman; A Holly
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.

Authors:  Gayle M Boxx; Thomas R Kozel; Casey T Nishiya; Mason X Zhang
Journal:  Infect Immun       Date:  2009-12-22       Impact factor: 3.441

6.  Proteolytic activation of the interleukin-1beta precursor by Candida albicans.

Authors:  A Beauséjour; D Grenier; J P Goulet; N Deslauriers
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

7.  The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein.

Authors:  T Meri; A M Blom; A Hartmann; D Lenk; S Meri; P F Zipfel
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

8.  Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans.

Authors:  M X Zhang; J E Cutler; Y Han; T R Kozel
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Increased C3 production in human monocytes after stimulation with Candida albicans is suppressed by granulocyte-macrophage colony-stimulating factor.

Authors:  A K Høgåsen; T G Abrahamsen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.

Authors:  Gayle M Boxx; Casey T Nishiya; Thomas R Kozel; Mason X Zhang
Journal:  Mol Immunol       Date:  2008-11-26       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.